BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017;5:709-17. [PMID: 28781064 DOI: 10.1016/S2213-8587(17)30258-9] [Cited by in Crossref: 227] [Cited by in F6Publishing: 240] [Article Influence: 37.8] [Reference Citation Analysis]
Number Citing Articles
1 Huang J, Ma KS, Wang L, Chiang C, Yang S, Wang C, Wang P. The Impact of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease. Cancers 2023;15:833. [DOI: 10.3390/cancers15030833] [Reference Citation Analysis]
2 Scheen AJ, Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? Diabetes Metab 2023;49:101419. [PMID: 36640828 DOI: 10.1016/j.diabet.2023.101419] [Reference Citation Analysis]
3 Cardoso H, Bello CT, Andrade L, Rosário FSD, Louro J, Nogueira C, Rodrigues E, Vieira NB, Carqueja T; et al., on behalf of the PICT2RE Investigators. High prevalence of cardiovascular disease and risk factors among type 2 diabetes patients followed in a hospital setting in Portugal: The PICT2RE observational study. Rev Port Cardiol 2023:S0870-2551(23)00049-5. [PMID: 36634764 DOI: 10.1016/j.repc.2022.04.011] [Reference Citation Analysis]
4 Gonzalez Perez A, Vizcaya D, Sáez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care 2023;11. [PMID: 36596641 DOI: 10.1136/bmjdrc-2022-003072] [Reference Citation Analysis]
5 Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab 2023;49:101418. [PMID: 36608816 DOI: 10.1016/j.diabet.2022.101418] [Reference Citation Analysis]
6 Abu-Alfa AK, Atallah PJ, Azar ST, Dagher EC, Echtay AS, El-Amm MA, Hazkial HG, Kassab RY, Medlej RC, Mohamad MA; Lebanese Consortium for Early, Comprehensive Management of Type 2 Diabetes (LCECMD). Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Ther 2023;14:11-28. [PMID: 36517708 DOI: 10.1007/s13300-022-01340-x] [Reference Citation Analysis]
7 Funck KL, Bjerg L, Isaksen AA, Sandbæk A, Grove EL. Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study. Cardiovasc Diabetol 2022;21:279. [PMID: 36496402 DOI: 10.1186/s12933-022-01713-3] [Reference Citation Analysis]
8 Scheen AJ. Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d’arythmies ventriculaires et de mort subite. Médecine des Maladies Métaboliques 2022. [DOI: 10.1016/j.mmm.2022.11.001] [Reference Citation Analysis]
9 Dissanayake H, Dilrukshi S, Ratnasamy V, Soysa P, Samarathunga T, Bandara P, De Silva L, Katulanda P. Empagliflozin in South Asians with type 2 diabetes: Real world data on effects on cardiometabolic parameters, safety and determinants of response to therapy from a diabetes practice in Sri Lanka. Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.11.005] [Reference Citation Analysis]
10 Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes Obes Metab 2022;24:2138-47. [PMID: 35676798 DOI: 10.1111/dom.14799] [Reference Citation Analysis]
11 Kishima H, Mine T, Fukuhara E, Kitagaki R, Asakura M, Ishihara M. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol 2022;8:1393-404. [PMID: 36424008 DOI: 10.1016/j.jacep.2022.08.004] [Reference Citation Analysis]
12 Butterly E, Wei L, Adler AI, Almazam SAM, Alsallumi K, Blackbourn LAK, Dias S, Hanlon P, Hughes K, Lewsey J, Lindsay R, McGurnaghan S, Petrie J, Phillippo D, Sattar N, Tomlinson LA, Welton N, Wild S, McAllister D. Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. BMJ Open 2022;12:e066491. [PMID: 36302574 DOI: 10.1136/bmjopen-2022-066491] [Reference Citation Analysis]
13 Cesaro A, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Oreglia JA, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Pizzi C, Barbato E, Calabrò P, Marfella R. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med 2022;9:1012220. [PMID: 36237914 DOI: 10.3389/fcvm.2022.1012220] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101390] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Baviera M, Foresta A, Colacioppo P, Macaluso G, Roncaglioni MC, Tettamanti M, Fortino I, Genovese S, Caruso I, Giorgino F. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovasc Diabetol 2022;21:162. [PMID: 35999556 DOI: 10.1186/s12933-022-01572-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zaini LM, Kartasasmita AS, Gondhowiardjo TD, Syukri M, Lesmana R. Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy. Expert Review of Ophthalmology. [DOI: 10.1080/17469899.2022.2111302] [Reference Citation Analysis]
17 Luo F, Sun L, Wang Z, Zhang Y, Li J, Chen Y, Dong J. Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation. Cardiovasc Drugs Ther 2022. [PMID: 35962156 DOI: 10.1007/s10557-022-07368-2] [Reference Citation Analysis]
18 Peyton KJ, Behnammanesh G, Durante GL, Durante W. Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. Int J Mol Sci 2022;23:8777. [PMID: 35955910 DOI: 10.3390/ijms23158777] [Reference Citation Analysis]
19 González-pérez A, Vizcaya D, Sáez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and Renal Outcomes among Patients with Type 2 Diabetes using SGLT2 Inhibitors added to Metformin: A Population-Based Cohort Study from the United Kingdom.. [DOI: 10.1101/2022.07.28.22278158] [Reference Citation Analysis]
20 Zügner E, Yang H, Kotzbeck P, Boulgaropoulos B, Sourij H, Hagvall S, Elmore CS, Esterline R, Moosmang S, Oscarsson J, Pieber TR, Peng X, Magnes C. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. IJMS 2022;23:7966. [DOI: 10.3390/ijms23147966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kwon CH, Kim YJ, Kim MJ, Cha MJ, Cho MS, Nam GB, Choi KJ, Kim J. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation. Am J Cardiol 2022:S0002-9149(22)00583-5. [PMID: 35810007 DOI: 10.1016/j.amjcard.2022.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. Yonsei Med J 2022;63:619-31. [PMID: 35748073 DOI: 10.3349/ymj.2022.63.7.619] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Han J, Luo L, Marcelina O, Kasim V, Wu S. Therapeutic angiogenesis-based strategy for peripheral artery disease. Theranostics 2022;12:5015-33. [PMID: 35836800 DOI: 10.7150/thno.74785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Fisher, M, Llano, and A, Mckay G. SGLT2 Inhibitors. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch5] [Reference Citation Analysis]
25 Goh LGH, Sun J, Ong BSK, Khoo D, Sum CF, Ng K. Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study. J Diabetes Metab Disord 2022;21:521-55. [PMID: 35673518 DOI: 10.1007/s40200-022-01004-4] [Reference Citation Analysis]
26 Jeon H, Lee A, Ha K. Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications. BioChip J. [DOI: 10.1007/s13206-022-00057-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rhee JJ, Han J, Montez-Rath ME, Kim SH, Cullen MR, Stafford RS, Winkelmayer WC, Chertow GM. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes Obes Metab 2022;24:928-37. [PMID: 35118793 DOI: 10.1111/dom.14657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Escobar C, Varela L, Palacios B, Capel M, Sicras-mainar A, Sicras-navarro A, Hormigo A, Alcázar R, Manito N, Botana M. Características clínicas, manejo y riesgo de complicaciones a un año en pacientes con insuficiencia cardíaca con y sin diabetes tipo 2 en España. Revista Clínica Española 2022;222:195-204. [DOI: 10.1016/j.rce.2021.04.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Attachaipanich T, Chattipakorn SC, Chattipakorn N. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure. J Cell Physiol 2022. [PMID: 35324001 DOI: 10.1002/jcp.30727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Luo LL, Han JX, Wu SR, Kasim V. Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function. Acta Pharmacol Sin 2022. [PMID: 35292769 DOI: 10.1038/s41401-022-00889-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yang L, Gabriel N, Hernandez I, Vouri SM, Kimmel SE, Bian J, Guo J. Identifying Patients at Risk of Acute Kidney Injury Among Medicare Beneficiaries With Type 2 Diabetes Initiating SGLT2 Inhibitors: A Machine Learning Approach. Front Pharmacol 2022;13:834743. [DOI: 10.3389/fphar.2022.834743] [Reference Citation Analysis]
32 Lv XH, Cong XX, Nan JL, Lu XM, Zhu QL, Shen J, Wang BB, Wang ZT, Zhou RY, Chen WA, Su L, Chen X, Li ZZ, Lin YN. Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice. Acta Pharmacol Sin 2022. [PMID: 35217814 DOI: 10.1038/s41401-022-00878-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, Altucci L, Napoli C. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res 2021;175:106039. [PMID: 34929299 DOI: 10.1016/j.phrs.2021.106039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
34 Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism 2021;127:154937. [PMID: 34808144 DOI: 10.1016/j.metabol.2021.154937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
35 Alkabbani W, Gamble JM, Eurich DT, Minhas-Sandhu JK, Shah BR, Alsabbagh MW, Zongo A. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs. Diabetes Metab 2021;48:101305. [PMID: 34808344 DOI: 10.1016/j.diabet.2021.101305] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Shao SC, Chang KC, Lin SJ, Chang SH, Hung MJ, Chan YY, Lai EC. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Cardiovasc Diabetol 2021;20:213. [PMID: 34688282 DOI: 10.1186/s12933-021-01406-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
37 Seong JM, Kim JJ, Kim HJ, Sohn HS. Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors. Front Pharmacol 2021;12:689885. [PMID: 34650428 DOI: 10.3389/fphar.2021.689885] [Reference Citation Analysis]
38 Zerovnik S, Kos M, Locatelli I. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study. BMJ Open 2021;11:e051549. [PMID: 34518273 DOI: 10.1136/bmjopen-2021-051549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Escobar C, Varela L, Palacios B, Capel M, Sicras-Mainar A, Sicras-Navarro A, Hormigo A, Alcázar R, Manito N, Botana M. Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Rev Clin Esp (Barc) 2021:S2254-8874(21)00129-6. [PMID: 34511336 DOI: 10.1016/j.rceng.2021.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Yildirim Şimşir I, Çetinkalp Ş, Soyaltin UE, Kandemir A, Seziş M. A Sweet Dream with SGLT2 Inhibitors. Turkish Journal of Diabetes and Obesity 2021;5:237-240. [DOI: 10.25048/tudod.900107] [Reference Citation Analysis]
41 Mascolo A, Scavone C, Scisciola L, Chiodini P, Capuano A, Paolisso G. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. Pharmacol Res 2021;172:105836. [PMID: 34418562 DOI: 10.1016/j.phrs.2021.105836] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
42 Huang JY, Yang SF, Wu PJ, Wang CH, Tang CH, Wang PH. Different Influences of Endometriosis and Pelvic Inflammatory Disease on the Occurrence of Ovarian Cancer. Int J Environ Res Public Health 2021;18:8754. [PMID: 34444500 DOI: 10.3390/ijerph18168754] [Reference Citation Analysis]
43 Schechter M, Melzer-Cohen C, Rozenberg A, Yanuv I, Chodick G, Karasik A, Kosiborod M, Mosenzon O. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovasc Diabetol 2021;20:169. [PMID: 34407822 DOI: 10.1186/s12933-021-01362-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
44 Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P; CVD-REAL Investigators and Study Group. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol 2021;20:159. [PMID: 34332558 DOI: 10.1186/s12933-021-01345-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
45 Sousa LS, Nascimento FDA, Rocha J, Rocha-parise M. Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences 2021. [DOI: 10.36660/ijcs.20200339] [Reference Citation Analysis]
46 Vrachatis DA, Papathanasiou KA, Iliodromitis KE, Giotaki SG, Kossyvakis C, Raisakis K, Kaoukis A, Lambadiari V, Avramides D, Reimers B, Stefanini GG, Cleman M, Giannopoulos G, Lansky A, Deftereos SG. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs 2021;81:1381-95. [PMID: 34297330 DOI: 10.1007/s40265-021-01565-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
47 Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol 2021;20:139. [PMID: 34243779 DOI: 10.1186/s12933-021-01323-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Sütő G, Molnár GA, Rokszin G, Fábián I, Kiss Z, Szekanecz Z, Poór G, Jermendy G, Kempler P, Wittmann I. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. BMJ Open Diabetes Res Care 2021;9:e001765. [PMID: 33472796 DOI: 10.1136/bmjdrc-2020-001765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Longato E, Di Camillo B, Sparacino G, Gubian L, Avogaro A, Fadini GP. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care 2020;8:e001451. [PMID: 32591373 DOI: 10.1136/bmjdrc-2020-001451] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
50 Zheng XD, Qu Q, Jiang XY, Wang ZY, Tang C, Sun JY. Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis. Am J Cardiovasc Drugs 2021;21:321-30. [PMID: 33001355 DOI: 10.1007/s40256-020-00441-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol 2021;20:83. [PMID: 33888126 DOI: 10.1186/s12933-021-01272-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
52 Kale S, Tahrani AA. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention? Metabol Open 2021;10:100082. [PMID: 33817616 DOI: 10.1016/j.metop.2021.100082] [Reference Citation Analysis]
53 Colosimo S, Ravaioli F, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver Int 2021;41:731-42. [PMID: 33497019 DOI: 10.1111/liv.14799] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
54 Varshney N, Billups SJ, Saseen JJ, Fixen CW. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. Ther Adv Drug Saf 2021;12:2042098621997703. [PMID: 33854754 DOI: 10.1177/2042098621997703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, Tung YC. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep 2021;11:7000. [PMID: 33772082 DOI: 10.1038/s41598-021-86516-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Caparrotta TM, Greenhalgh AM, Osinski K, Gifford RM, Moser S, Wild SH, Reynolds RM, Webb DJ, Colhoun HM. Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Ther 2021;12:991-1028. [PMID: 33665777 DOI: 10.1007/s13300-021-01004-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
57 Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS One 2021;16:e0244689. [PMID: 33606705 DOI: 10.1371/journal.pone.0244689] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
58 Zaibi N, Li P, Xu SZ. Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells. PLoS One 2021;16:e0247234. [PMID: 33606763 DOI: 10.1371/journal.pone.0247234] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
59 Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Curr Cardiol Rev 2020;16:258-65. [PMID: 31362691 DOI: 10.2174/1573403X15666190730094215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bonora BM, Raschi E, Avogaro A, Fadini GP. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol 2021;20:39. [PMID: 33573667 DOI: 10.1186/s12933-021-01243-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
61 Regassa LD, Tola A, Ayele Y. Prevalence of Cardiovascular Disease and Associated Factors Among Type 2 Diabetes Patients in Selected Hospitals of Harari Region, Eastern Ethiopia. Front Public Health 2020;8:532719. [PMID: 33614562 DOI: 10.3389/fpubh.2020.532719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
62 McEwan P, Morgan AR, Boyce R, Bergenheim K, Gause-Nilsson IAM, Bhatt DL, Leiter LA, Johansson PA, Mosenzon O, Cahn A, Wilding JPH. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab 2021;23:1020-9. [PMID: 33368855 DOI: 10.1111/dom.14308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
63 Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. [PMID: 33441402 DOI: 10.1136/bmj.m4573] [Cited by in Crossref: 185] [Cited by in F6Publishing: 191] [Article Influence: 92.5] [Reference Citation Analysis]
64 Vigili de Kreutzenberg S. Silent coronary artery disease in type 2 diabetes: a narrative review on epidemiology, risk factors, and clinical studies. Exploration of Medicine. [DOI: 10.37349/emed.2021.00029] [Reference Citation Analysis]
65 Domek M, Javed S, Gumprecht J, Lip GY. Diabetes mellitus and atrial fibrillation—Untying the Gordian Knot. Diabetes and Cardiovascular Disease 2021. [DOI: 10.1016/b978-0-12-817428-9.00004-8] [Reference Citation Analysis]
66 Onmez A, Gokosmanoglu F, Baycelebi G, Arıkan AA. Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients. Aging Male 2020;23:1246-50. [PMID: 32342718 DOI: 10.1080/13685538.2020.1758657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol 2020;19:188. [PMID: 33158436 DOI: 10.1186/s12933-020-01162-w] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
68 Funck KL, Knudsen JS, Hansen TK, Thomsen RW, Grove EL. Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. Diabetes Obes Metab 2021;23:520-9. [PMID: 33140907 DOI: 10.1111/dom.14245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
69 Jeon JY, Ha KH, Kim DJ. Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2021;45:505-14. [PMID: 33120439 DOI: 10.4093/dmj.2020.0057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
70 Nalugo M, Harroun N, Li C, Belaygorod L, Semenkovich CF, Zayed MA. Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes. Vasc Med 2021;26:131-8. [PMID: 33095685 DOI: 10.1177/1358863X20961153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab 2021;23:75-85. [PMID: 32893440 DOI: 10.1111/dom.14189] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
72 Lee TW, Lee TI, Lin YK, Chen YC, Kao YH, Chen YJ. Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. Cell Mol Life Sci 2021;78:923-34. [PMID: 32965513 DOI: 10.1007/s00018-020-03648-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
73 Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care 2019;7:e000742. [PMID: 32043472 DOI: 10.1136/bmjdrc-2019-000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
74 Bramlage P, Tittel SR, Wagner C, König K, Raddatz D, Weber-Lauffer R, Erath D, Hilgenberg J, Spies C, Danne T, Gabler M, Foersch J, Ley L, Seufert J. The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany. BMJ Open Diabetes Res Care 2020;8:e001486. [PMID: 32719080 DOI: 10.1136/bmjdrc-2020-001486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 De Nicola L, Gabbai FB, Garofalo C, Conte G, Minutolo R. Nephroprotection by SGLT2 Inhibition: Back to the Future? J Clin Med 2020;9:E2243. [PMID: 32679744 DOI: 10.3390/jcm9072243] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
76 Dubrofsky L, Srivastava A, Cherney DZ. Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Can J Kidney Health Dis 2020;7:2054358120935701. [PMID: 32637144 DOI: 10.1177/2054358120935701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
77 Seong JM, Kim JJ, Kim HJ, Sohn HS. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. Cardiovasc Diabetol 2020;19:95. [PMID: 32571319 DOI: 10.1186/s12933-020-01060-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
78 Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab 2020;22:1607-18. [PMID: 32363737 DOI: 10.1111/dom.14074] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 18.7] [Reference Citation Analysis]
79 Martens P, Janssens J, Ramaekers J, Dupont M, Mullens W. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiol 2020;75:211-7. [PMID: 30736724 DOI: 10.1080/00015385.2019.1569313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Anderson JE. Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. Diabetes Spectr 2020;33:165-74. [PMID: 32425454 DOI: 10.2337/ds19-0031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Giorgino F, Vora J, Fenici P, Solini A. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients? Diabetes Obes Metab 2020;22:1481-95. [PMID: 32285611 DOI: 10.1111/dom.14055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
82 Elsisi GH, Anwar MM, Khattab M, Elebrashy I, Wafa A, Elhadad H, Awad M, Carapinha JL. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt. J Med Econ 2020;23:908-14. [PMID: 32364032 DOI: 10.1080/13696998.2020.1764571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
83 Yang Y, Zhao C, Ye Y, Yu M, Qu X. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes. Front Endocrinol (Lausanne) 2020;11:190. [PMID: 32351447 DOI: 10.3389/fendo.2020.00190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
84 Behnammanesh G, Durante GL, Khanna YP, Peyton KJ, Durante W. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. Redox Biol 2020;32:101527. [PMID: 32278282 DOI: 10.1016/j.redox.2020.101527] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
85 Shen Y, Zhou J, Shi L, Nauman E, Katzmarzyk PT, Price-Haywood EG, Horswell R, Chu S, Yang S, Bazzano AN, Nigam S, Hu G. Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease. Diabetes Obes Metab 2020;22:1197-206. [PMID: 32166884 DOI: 10.1111/dom.14025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
86 Deng B, Henan University of Science and Technology, Luoyang, PRС, Kireev V, Melentyeva K, Kovalenko I, Pakhomov O, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, SI ‘I.I. Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine’, Kharkiv, Ukraine, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine. Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation. Probl Cryobiol Cryomed 2020;30:034-046. [DOI: 10.15407/cryo30.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. J Clin Med 2020;9:E912. [PMID: 32225082 DOI: 10.3390/jcm9040912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
88 Rоsul ММ, Bletskan ММ, Ivano NV, Korabelschykova MO, Rubtsova YІ. PRIORITIES OF ANTI-HYPERGLYCAEMIC DRUG THERAPY IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE. Wiad Lek 2020;73:609-613. [DOI: 10.36740/wlek202003139] [Reference Citation Analysis]
89 Sato T, Aizawa Y, Yuasa S, Fujita S, Ikeda Y, Okabe M. The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial. J Atheroscler Thromb 2020;27:1348-58. [PMID: 32115470 DOI: 10.5551/jat.48009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
90 Sujanani SM, Elfishawi MM, Zarghamravanbaksh P, Castillo FJC, Reich DM. Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. Case Rep Endocrinol 2020;2020:6724504. [PMID: 32123591 DOI: 10.1155/2020/6724504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
91 Wilkinson S, Williamson E, Pokrajac A, Fogarty D, Stirnadel-Farrant H, Smeeth L, Douglas IJ, Tomlinson LA. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care. Diabetes Obes Metab 2020;22:847-56. [PMID: 31957254 DOI: 10.1111/dom.13970] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
92 Halimi S. Place des nouveaux antidiabétiques dans les récents Consensus sur le diabète de type 2 : EASD/ADA et ESC 2019. Est-ce bien raisonnable et faisable ? Médecine des Maladies Métaboliques 2020;14:1-3. [DOI: 10.1016/j.mmm.2019.12.019] [Reference Citation Analysis]
93 Lin Y, Nan J, Shen J, Lv X, Chen X, Lu X, Zhang C, Xiang P, Wang Z, Li Z. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells. EBioMedicine 2020;52:102637. [PMID: 31981975 DOI: 10.1016/j.ebiom.2020.102637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
94 Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes Metab Syndr Obes 2020;13:161-74. [PMID: 32021362 DOI: 10.2147/DMSO.S233538] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 23.0] [Reference Citation Analysis]
95 Du C, He C, Dong L, Zheng S, Wang W, Zheng C, Wang S, Lin M, Yang S, Li X, Li Z, Liu C. Associations of apnea hypopnea index and educational attainments with microvascular complications in patients with T2DM. Endocrine 2020;67:363-73. [PMID: 31927752 DOI: 10.1007/s12020-020-02192-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
96 Avgerinos I, Liakos A, Tsapas A, Bekiari E. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes Metab Syndr Obes 2019;12:2549-57. [PMID: 31819580 DOI: 10.2147/DMSO.S190356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
97 Canivell S, Mata-Cases M, Vlacho B, Gratacòs M, Real J, Mauricio D, Franch-Nadal J. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. J Diabetes Res 2019;2019:2018374. [PMID: 31815146 DOI: 10.1155/2019/2018374] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
98 Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs 2019;79:1135-46. [PMID: 31236801 DOI: 10.1007/s40265-019-01148-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
99 Handelsman Y. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther 2019;36:2567-86. [PMID: 31444707 DOI: 10.1007/s12325-019-01054-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Shao SC, Chang KC, Hung MJ, Yang NI, Chan YY, Chen HY, Kao Yang YH, Lai EC. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovasc Diabetol 2019;18:120. [PMID: 31551068 DOI: 10.1186/s12933-019-0919-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
101 Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol 2019;11:133-43. [PMID: 31572020 DOI: 10.2147/CPAA.S172353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
102 Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res 2018;122:1439-59. [PMID: 29748368 DOI: 10.1161/CIRCRESAHA.117.311588] [Cited by in Crossref: 171] [Cited by in F6Publishing: 181] [Article Influence: 42.8] [Reference Citation Analysis]
103 Schernthaner G, Karasik A, Abraitienė A, Ametov AS, Gaàl Z, Gumprecht J, Janež A, Kaser S, Lalić K, Mankovsky BN, Moshkovich E, Past M, Prázný M, Radulian G, Smirčić Duvnjak L, Tkáč I, Trušinskis K. Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. Cardiovasc Diabetol 2019;18:115. [PMID: 31472683 DOI: 10.1186/s12933-019-0920-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
104 Pasternak B, Ueda P, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:l4772. [PMID: 31467044 DOI: 10.1136/bmj.l4772] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
105 Patel DK, Strong J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther 2019;10:1771-92. [PMID: 31456166 DOI: 10.1007/s13300-019-00686-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
106 Norhammar A, Bodegard J, Nyström T, Thuresson M, Rikner K, Nathanson D, Eriksson JW. Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes Obes Metab 2019;21:2651-9. [PMID: 31379124 DOI: 10.1111/dom.13852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
107 Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J Environ Res Public Health 2019;16:E2965. [PMID: 31426529 DOI: 10.3390/ijerph16162965] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 20.0] [Reference Citation Analysis]
108 Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovasc Diabetol 2019;18:106. [PMID: 31412874 DOI: 10.1186/s12933-019-0910-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
109 Kroemer G, López-Otín C, Madeo F, de Cabo R. Carbotoxicity-Noxious Effects of Carbohydrates. Cell 2018;175:605-14. [PMID: 30340032 DOI: 10.1016/j.cell.2018.07.044] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
110 Ahn CH, Lim S. Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. J Stroke 2019;21:139-50. [PMID: 31161759 DOI: 10.5853/jos.2019.00038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 Adis Medical Writers. Aim to normalize glucose levels and reduce cardiovascular mortality when managing type 2 diabetes in the elderly. Drugs Ther Perspect 2019;35:271-277. [DOI: 10.1007/s40267-019-00619-7] [Reference Citation Analysis]
112 Khan MS, Butler J. Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. J Diabetes 2019;11:601-4. [PMID: 31044514 DOI: 10.1111/1753-0407.12932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Halimi S. Fable « L’exception française et les SGLT2-i ». Où se situe la perte de chance ? Médecine des Maladies Métaboliques 2019;13:229-231. [DOI: 10.1016/s1957-2557(19)30065-3] [Reference Citation Analysis]
114 Tamargo J. Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. Eur Cardiol. 2019;14:23-32. [PMID: 31131034 DOI: 10.15420/ecr.2018.34.2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
115 Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab 2019;17:e84353. [PMID: 31372172 DOI: 10.5812/ijem.84353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
116 Behnammanesh G, Durante ZE, Peyton KJ, Martinez-Lemus LA, Brown SM, Bender SB, Durante W. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation. Front Pharmacol 2019;10:362. [PMID: 31057401 DOI: 10.3389/fphar.2019.00362] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
117 Bauduceau B, Bordier L, Bringer J, Chabrier G, Charbonnel B, Cosson E, Darmon P, Detournay B, Fontaine P, Gourdy P, Grimaldi A, Guerci B, Hanaire H, Penfornis A, Riveline J, Scheen A. Prise de position de la Société Francophone du Diabète (SFD) : évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. Médecine des Maladies Métaboliques 2019;13:195-209. [DOI: 10.1016/s1957-2557(19)30056-2] [Reference Citation Analysis]
118 Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, Liew D. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep 2019;9:3256. [PMID: 30824788 DOI: 10.1038/s41598-019-40191-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
119 Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha SS. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. Heart Fail Rev 2018;23:445-59. [PMID: 29270818 DOI: 10.1007/s10741-017-9666-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
120 Longo M, Bellastella G, Maiorino MI, Meier JJ, Esposito K, Giugliano D. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Front Endocrinol (Lausanne) 2019;10:45. [PMID: 30833929 DOI: 10.3389/fendo.2019.00045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
121 Norhammar A, Bodegård J, Nyström T, Thuresson M, Nathanson D, Eriksson JW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes Obes Metab 2019;21:1136-45. [PMID: 30609272 DOI: 10.1111/dom.13627] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
122 Garg SK, Giordano D. New Medications for the Treatment of Diabetes. Diabetes Technol Ther 2019;21:S160-71. [PMID: 30785325 DOI: 10.1089/dia.2019.2513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Chen SY, Liu JW, Wang YH, Huang JY, Chen SC, Yang SF, Wang PH. The Conditions Under Which Piracetam Is Used and the Factors That Can Improve National Institute of Health Stroke Scale Score in Ischemic Stroke Patients and the Importance of Previously Unnoticed Factors From a Hospital-Based Observational Study in Taiwan. J Clin Med 2019;8:E122. [PMID: 30669522 DOI: 10.3390/jcm8010122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Birkeland KI, Bodegard J, Norhammar A, Kuiper JG, Georgiado E, Beekman-Hendriks WL, Thuresson M, Pignot M, Herings RMC, Kooy A. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes Metab 2019;21:968-74. [PMID: 30537226 DOI: 10.1111/dom.13612] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
125 Vidić N, Đenić A. Inhibitor natrijum-glukoznog kotransportera tipa 2 - dapagliflozin u terapiji obolelih od diabetes mellitus tipa 2. Med gl Spec bol štit Zlatibor 2019;24:29-39. [DOI: 10.5937/medgla1973029v] [Reference Citation Analysis]
126 Coutiño-castelán D, Abundes-velasco A, de los Santos FD, Arias Sánchez EA, González CM, Ortiz AM, Morales JL, de la Cruz JLB, Fonseca CEH, Sánchez PC. Diabetes and Cardiovascular Disease. The Diabetes Textbook 2019. [DOI: 10.1007/978-3-030-11815-0_46] [Reference Citation Analysis]
127 Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257 [PMID: 30588287 DOI: 10.4239/wjd.v9.i12.252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
128 O'Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open 2018;1:e186125. [PMID: 30646315 DOI: 10.1001/jamanetworkopen.2018.6125] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
129 Halimi S. Inhibiteurs des SGLT2 : l’effet classe se confirme. Médecine des Maladies Métaboliques 2018;12:637-639. [DOI: 10.1016/s1957-2557(18)30171-8] [Reference Citation Analysis]
130 Morse C, Sze D, Patel D, Goldman J. Nonglycemic Outcomes of Antidiabetic Medications. Clin Diabetes 2019;37:131-41. [PMID: 31057219 DOI: 10.2337/cd18-0015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
131 Fadini GP, Solini A, Manca ML, Penno G, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab 2019;21:252-60. [PMID: 30136354 DOI: 10.1111/dom.13508] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
132 Kobalava ZD, Kiyakbaev GК. TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY? Russ J Cardiol 2018. [DOI: 10.15829/1560-4071-2018-8-79-91] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
133 Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW. Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. Endocrinol Diabetes Metab 2018;1:e00036. [PMID: 30815564 DOI: 10.1002/edm2.36] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
134 Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61:2118-2125. [PMID: 30132031 DOI: 10.1007/s00125-018-4663-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 96] [Article Influence: 18.2] [Reference Citation Analysis]
135 Raschi E, Poluzzi E, Fadini GP, Marchesini G, De Ponti F. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab 2018;20:2711-23. [PMID: 30003655 DOI: 10.1111/dom.13468] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
136 Mazón Ramos P. New pharmacological approaches for cardiovascular risk. Medicina Clínica (English Edition) 2018;151:145-147. [DOI: 10.1016/j.medcle.2017.12.035] [Reference Citation Analysis]
137 Mazón Ramos P. Nuevos enfoques farmacológicos para el riesgo cardiovascular. Medicina Clínica 2018;151:145-147. [DOI: 10.1016/j.medcli.2017.12.015] [Reference Citation Analysis]
138 Nasiri-Ansari Ν, Dimitriadis GK, Agrogiannis G, Perrea D, Kostakis ID, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol 2018;17:106. [PMID: 30049285 DOI: 10.1186/s12933-018-0749-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
139 Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L, Clauson P, Fenici P, Hammar N, Medina J. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med 2018;16:116. [PMID: 30008267 DOI: 10.1186/s12916-018-1085-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
140 Jia X, Mehta PB, Ye Y, Alam M, Birnbaum Y, Bajaj M. SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. Curr Diab Rep 2018;18:63. [PMID: 29995242 DOI: 10.1007/s11892-018-1038-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
141 Thomas MC. Perspective Review: Type 2 Diabetes and Readmission for Heart Failure. Clin Med Insights Cardiol 2018;12:1179546818779588. [PMID: 29899670 DOI: 10.1177/1179546818779588] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
142 Igel LI, Saunders KH, Fins JJ. Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. Curr Atheroscler Rep 2018;20:39. [PMID: 29785665 DOI: 10.1007/s11883-018-0740-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
143 Gallwitz B. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data. Eur Endocrinol 2018;14:17-23. [PMID: 29922347 DOI: 10.17925/EE.2018.14.1.17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
144 Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Diabetes Obes Metab 2018;20:1983-7. [PMID: 29569378 DOI: 10.1111/dom.13299] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 11.2] [Reference Citation Analysis]
145 Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA 2018;319:1580-91. [PMID: 29677303 DOI: 10.1001/jama.2018.3024] [Cited by in Crossref: 233] [Cited by in F6Publishing: 241] [Article Influence: 46.6] [Reference Citation Analysis]
146 Cavaiola TS, Pettus J. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. Diabetes Metab Syndr Obes 2018;11:133-48. [PMID: 29695924 DOI: 10.2147/DMSO.S154602] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
147 Nordestgaard BG, Cosentino F, Landmesser U, Laufs U. The year in cardiology 2017: prevention. Cardiologia Croatica 2018;13:79-98. [DOI: 10.15836/ccar2018.79] [Reference Citation Analysis]
148 Avogaro A, De Kreutzenberg SV, Fadini GP. The impact of glucose-lowering medications on cardiovascular disease. Cardiovasc Endocrinol Metab 2018;7:13-7. [PMID: 31646273 DOI: 10.1097/XCE.0000000000000139] [Reference Citation Analysis]
149 Halimi S. Répondeurs et non-répondeurs aux antidiabétiques. Dans l’attente de la pharmacogénétique, savoir réévaluer leur efficacité, surtout en regard de leurs coûts. Médecine des Maladies Métaboliques 2018;12:5-7. [DOI: 10.1016/s1957-2557(18)30001-4] [Reference Citation Analysis]
150 Scheen A. Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Médecine des Maladies Métaboliques 2018;12:22-30. [DOI: 10.1016/s1957-2557(18)30005-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
151 Bagi Z. Too much TRAFfic at the crossroads of diabetes and endothelial dysfunction. Am J Physiol Heart Circ Physiol 2018;314:H65-7. [PMID: 29101184 DOI: 10.1152/ajpheart.00614.2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
152 MacIsaac RJ, Ekinci EI. Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world. Ann Transl Med 2017;5:474. [PMID: 29285507 DOI: 10.21037/atm.2017.10.11] [Reference Citation Analysis]
153 Schernthaner G, Khunti K, Lotan C, Burnier M, Drexel H, Prázný M. Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). Ther Clin Risk Manag 2017;13:1569-76. [PMID: 29276388 DOI: 10.2147/TCRM.S144362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
154 Thewjitcharoen Y, Yenseung N, Malidaeng A, Nakasatien S, Chotwanvirat P, Krittiyawong S, Wanothayaroj E, Himathongkam T. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. Diabetol Metab Syndr 2017;9:96. [PMID: 29213337 DOI: 10.1186/s13098-017-0297-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
155 Røder ME. Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. Ther Adv Chronic Dis 2018;9:33-50. [PMID: 29344329 DOI: 10.1177/2040622317735283] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
156 Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation 2017;136:1643-58. [PMID: 29061576 DOI: 10.1161/CIRCULATIONAHA.117.030012] [Cited by in Crossref: 260] [Cited by in F6Publishing: 279] [Article Influence: 43.3] [Reference Citation Analysis]
157 Saleem F. Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus. Cureus. 2017;9:e1751. [PMID: 29226041 DOI: 10.7759/cureus.1751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
158 . SGLT2 inhibitors and cardiovascular outcomes. DTB 2017;55:111.2-112. [DOI: 10.1136/dtb.2017.10.0534] [Reference Citation Analysis]
159 Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 2018;20:344-51. [PMID: 28771923 DOI: 10.1111/dom.13077] [Cited by in Crossref: 132] [Cited by in F6Publishing: 140] [Article Influence: 22.0] [Reference Citation Analysis]
160 Xu H, Cao WZ, Bai YY, Cao RH, Tian L, Cao F, Fan L. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in elderly patients with comorbid coronary heart disease and diabetes mellitus. J Geriatr Cardiol 2021;18:440-8. [PMID: 34220973 DOI: 10.11909/j.issn.1671-5411.2021.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Chen KC, Yin WH, Wu CC, Chan SH, Wu YW, Yang Wang K, Chang KC, Hwang JJ, Voon WC, Hsieh IC, Chong JT, Lin WS, Hsu CN, Ueng KC, Hsia CP, Liu JC, Yeh JS, Mar GY, Shih JY, Kuo JY, Tsao HM, Tseng WK, Yang CH, Chang CC, Chiang CE, Lei MH, Lin JF, Shyu KG. In-Hospital Implementation of Evidence-Based Medications is Associated with Improved Survival in Diabetic Patients with Acute Coronary Syndrome - Data from TSOC ACS-DM Registry. Acta Cardiol Sin 2018;34:211-23. [PMID: 29844642 DOI: 10.6515/ACS.201805_34(3).20180207B] [Cited by in F6Publishing: 10] [Reference Citation Analysis]